Simon T - Search Results

1

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK; INRG Task Force. Cohn SL, et al. Among authors: simon t. J Clin Oncol. 2009 Jan 10;27(2):289-97. doi: 10.1200/JCO.2008.16.6785. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047291 Free PMC article.

2

Testicular and paratesticular involvement by metastatic neuroblastoma.

Simon T, Hero B, Berthold F. Simon T, et al. Cancer. 2000 Jun 1;88(11):2636-41. doi: 10.1002/1097-0142(20000601)88:11<2636::aid-cncr28>3.0.co;2-k. Cancer. 2000. PMID: 10861443 Review.

3

Metastatic neuroblastoma in infancy: what does the pattern of metastases contribute to prognosis?

Hero B, Simon T, Horz S, Berthold F. Hero B, et al. Among authors: simon t. Med Pediatr Oncol. 2000 Dec;35(6):683-7. doi: 10.1002/1096-911x(20001201)35:6<683::aid-mpo43>3.0.co;2-f. Med Pediatr Oncol. 2000. PMID: 11107146

4

The incidence of hearing impairment after successful treatment of neuroblastoma.

Simon T, Hero B, Dupuis W, Selle B, Berthold F. Simon T, et al. Klin Padiatr. 2002 Jul-Aug;214(4):149-52. doi: 10.1055/s-2002-33179. Klin Padiatr. 2002. PMID: 12165893

5

Neuroblastoma preoperatively treated as nephroblastoma: does inadequate therapy worsen the prognosis?

Hero B, Graf N, Simon T, Weirich A, Tröger J, Berthold F. Hero B, et al. Among authors: simon t. Klin Padiatr. 2002 Jul-Aug;214(4):157-61. doi: 10.1055/s-2002-33182. Klin Padiatr. 2002. PMID: 12165895 Clinical Trial.

6

Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age.

Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T, Spix C. Berthold F, et al. Among authors: simon t. Cancer Lett. 2003 Jul 18;197(1-2):11-7. doi: 10.1016/s0304-3835(03)00076-4. Cancer Lett. 2003. PMID: 12880954

7

Tumour markers are poor predictors for relapse or progression in neuroblastoma.

Simon T, Hero B, Hunneman DH, Berthold F. Simon T, et al. Eur J Cancer. 2003 Sep;39(13):1899-903. doi: 10.1016/s0959-8049(03)00376-9. Eur J Cancer. 2003. PMID: 12932669

8

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.

Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F. Simon T, et al. J Clin Oncol. 2004 Sep 1;22(17):3549-57. doi: 10.1200/JCO.2004.08.143. J Clin Oncol. 2004. PMID: 15337804

9

New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.

Simon T, Spitz R, Faldum A, Hero B, Berthold F. Simon T, et al. J Pediatr Hematol Oncol. 2004 Dec;26(12):791-6. J Pediatr Hematol Oncol. 2004. PMID: 15591897

10

Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy.

Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F. Simon T, et al. Klin Padiatr. 2005 May-Jun;217(3):147-52. doi: 10.1055/s-2005-836518. Klin Padiatr. 2005. PMID: 15858706 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,777 results

Search Page